Protagonist Therapeutics Inc (PTGX) Shares Outstanding 2014–TTM

Name: Protagonist Therapeutics Inc (PTGX) shares outstanding history 2014-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Protagonist Therapeutics Inc annual shares outstanding for fiscal 2025 was 64 million shares, a decrease of 1.5% from 65 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

PTGX Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31
Shares Outstanding (M)	—	64M	65M	57M	49M	46M	34M	26M	22M	18M	7M	6M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PTGX Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	—	70M	64M	64M	64M	63M	66M	62M	61M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

SMMT Shares Outstanding — Summit Therapeutics PLC
CYTK Shares Outstanding — Cytokinetics Inc
PRAX Shares Outstanding — Praxis Precision Medicines Inc
APGE Shares Outstanding — Apogee Therapeutics, Inc. Common Stock
KRYS Shares Outstanding — Krystal Biotech Inc
KYMR Shares Outstanding — Kymera Therapeutics Inc

More PTGX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All PTGX financial statements → Interactive PTGX charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.